Manmeet Ahluwalia
Baptist Health Herbert Wertheim Cancer Institute · Miami Cancer Institute/Baptist Health South Florida · Miami Cancer Institute, Baptist Health South Florida
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Manmeet Ahluwalia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:09 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07454668 · Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain MetastasesBaptist Health South Florida · not yet recruiting · Breast Cancer, HER2-positive Breast Cancer, Brain Metastases · principal investigator
- Ph2NCT06991101 · Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed GlioblastomaBaptist Health South Florida · recruiting · Glioblastoma, Brain Cancer, Glioblastoma Multiforme · principal investigator
- Ph1NCT05553522 · Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast CancerBaptist Health South Florida · terminated · Brain Metastases, HER2-positive Breast Cancer · principal investigator
- Ph3NCT05317858 · Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsInSightec · recruiting · Brain Tumor, Non Small Cell Lung Cancer · principal investigator
- Ph1NCT02880410 · Feasibility Study on LITT for Newly Diagnosed GlioblastomaMonteris Medical · terminated · Glioblastoma · principal investigator
- Ph3NCT02831959 · Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).NovoCure GmbH · completed · Brain Metastases From Non-small Cell Lung Cancer (NSCLC) · principal investigator
- Ph2NCT02743078 · Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent GlioblastomaRTOG Foundation, Inc. · terminated · Glioblastoma, Glioma, Gliosarcoma · principal investigator
- Ph1NCT02575794 · Terameprocol in Treating Patients With Recurrent High Grade GliomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · High Grade Glioma (III or IV) · principal investigator
- Ph2NCT02395692 · Methoxyamine and Temozolomide in Treating Patients With Recurrent GlioblastomaNational Cancer Institute (NCI) · terminated · Adult Brain Glioblastoma · principal investigator
- Ph2NCT01973062 · Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin LymphomaCase Comprehensive Cancer Center · terminated · Primary Central Nervous System Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT01905228 · A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid NeoplasmIncuron · completed · Solid Tumors, Glioblastoma · principal investigator
- Ph2NCT01753713 · Dovitinib in Treating Patients With Recurrent or Progressive GlioblastomaManmeet Ahluwalia, MD · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Adult Brain Tumor Consortium (ABTC)UM1CA137443 · NCI · JOHNS HOPKINS UNIVERSITY · PI STUART A GROSSMAN · fiscal years 2014 to 2020Named on NCT02575794, NCT02395692
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 12:09 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- 2,180 citationsRCR 79.4
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.JAMA Oncol · 20201,288 citationsRCR 55.9
- Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article.J Neurosurg · 2013199 citationsRCR 7.5
- Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.J Neurooncol · 2010155 citationsRCR 3.8
- Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.J Clin Oncol · 2023148 citationsRCR 13.7
- A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.Neuro Oncol · 2018124 citationsRCR 4.5
- Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.Neuro Oncol · 2018116 citationsRCR 4.0
- Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.JCI Insight · 2019103 citationsRCR 3.5
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Neuro Oncol · 201382 citationsRCR 2.4
- 77 citationsRCR 2.3